Cost effectiveness of levocetirizine in chronic idiopathic urticaria: A pooled analysis of two randomised controlled trials

Clinical Drug Investigation

Volumn 26, Issue 1, 2006, Pages 1-11

  Kapp, Alexander ^a   Demarteau, Nadia ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOCETIRIZINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; ECONOMIC ASPECT; EXPERIENCE; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT; PRIORITY JOURNAL; PRODUCTIVITY; SOCIETY; STATISTICAL ANALYSIS; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; ANTI-ALLERGIC AGENTS; CETIRIZINE; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URTICARIA;

EID: 30744469358     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626010-00001     Document Type: Article

References (31)

1. Grattan CEH, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-57
2. Zuberbier T, Greaves MW, Juhlin L, et al. Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001; 6 (2): 123-7
3. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136(2): 197-201
4. Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opinion Allergy Clin Immunol 2004; 4: 387-96
5. Kapp A, Wedi B. Chronic urticaria: clinical aspects, and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004; 3: 502-8
6. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000; 43 (1 Pt 1): 24-30
7. Monroe W. Eugene. The role of antihistamines in the treatment of chronic urticaria. J Allergy Clin Immunol 1990; 86: 662-5
8. Klimek L. Potential of levocetirizine in the relief of nasal congestion. Int J Clin Pract 2005; 59: 721-9
9. Denham KJ, Boutsiouki P, Clough GF, et al. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52: 424-7
10. Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56: 388-94
11. Larbig M, Stamm H, Hohlfeld J, et al. Levocetirizine but not desloratadine inhibits histamine-induced changes of nasal tem-perature measured by facial thermography: a pilot study [abstract no. 982]. Allergy 2003; 58: 283
12. Klos K, Kruszewski J, Bant A. The effect of various antihistamines after a single and a continuous (over 5 days) administration on the histamine-induced wheal, flare and skin blood flow: a randomised, double-blind, placebo controlled trial [abstract no. 536]. Allergy Clin Immunol Int 2005; S1: 202-3
13. Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: a suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 190-7
14. Larbig M, Stamm H, Casper A, et al. Twenty-four hour anti-H1 activity of levocetirizine measured by thermography is superior to fexofenadine [abstract no. 248]. Abstract book of the XXIII EAACI Congress, Amsterdam, 2004, 80
15. Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50-7
16. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004; 58: 109-18
17. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy 2004; 34: 958-64
18. Ciprandi G, Cirillo I, Vizzaccaro A, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study. Int Immunopharmacol 2005; 99 (12): 1606-12
19. Horak F, Zieglmayer PU, Zieglmayer R, et al. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005; 60: 24-31
20. Kapp A, Pichler JW. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized double-blind placebo controlled parallel multicenter study. Int J Dermatol 2005. In press
21. Kapp A, Wedi B. Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine. J Drugs Dermatol 2004; 3: 632-9
22. Internet sites www.vidialab.net, www.le-pmsi.org, www.ameli.fr, and www.insee.fr [Accessed 2003 May 23]
23. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13 (1 pt 1): 1-7
24. Demarteau N, Gauthier A. Philippart D, et al. Data on file. Health economic dossier of levocetirizine (Xyzal®) in chronic idopathic urticaria. Final 22-06-04. UCB Report No. RRCE04G1503
25. Huitema BE. Rank analysis of covariance. In: The analysis of covariance and alternatives. New York: John Wiley & Sons, 1980 Sep: Chap. 12: 255-269
26. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000; 19 (23): 3219-36
27. Davison AC, Hinkley V. Bootstrap methods and their applications. Cambridge: Cambridge University Press, 1997: Chap. 10.5
28. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med 1996; 15 (13): 1447-58
29. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6 (4): 327-40
30. Pichler WJ, Van Hammée G. Improvement of health-related quality of life in chronic idiopathic urticaria during treatment with levocetirizine [abstract no. 644]. Allergy Clin Immunol Int 2005; S1: 242
31. Rutten van Molken MP, Van Doorslaer EK, Jansen MC, et al. Cost and effects of inhaled corticosteroids and bronchodilators in asthma and COPD. Am J Respir Crit Care Med 1995; 151: 975-82